Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company dedicated to improving outcomes for cancer patients by inhibiting critical oncogenic pathways at multiple points. On February 17, 2026, the company completed the acquisition of Faeth Therapeutics, which is also a clinical-stage biotechnology company focused on developing multi-node therapies that target tumor metabolism and signaling. This acquisition integrated Faeth's primary asset, PIKTOR, into Sensei's development pipeline. PIKTOR is a proprietary investigational all-oral combination of serabelisib and sapanisertib, designed to inhibit multiple nodes within the PI3K/AKT/mTOR pathway. In connection with the acquisition, Sensei Biotherapeutics, Inc. secured $200 million in gross proceeds through a private placement financing in 2026. This financing was supported by a diverse group of investors, including prominent life sciences funds such as B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, and Vivo Capital, with the aim of advancing PIKTOR through significant clinical milestones.